New research challenges quality control standards for umbilical cord blood

Written by Regenerative Medicine

The peer-reviewed study from Burst Biologics, published in Regenerative Medicine, outlines future safety and potency benchmarks for umbilical cord blood-sourced allografts. Burst Biologics (ID, USA), a globally recognized institute in pharmaceutical research and tissue bank that services communities across the U.S., has published a research study entitled “Characterization of an umbilical cord blood sourced product suitable for allogeneic applications” in the prestigious peer-reviewed journal Regenerative Medicine. This study is part of Burst Biologics’ ongoing commitment to the production of groundbreaking research.    The article provides a comprehensive overview of the quality attributes, clinical suitability, and efficacy of BioBurst Rejuv, an...

To view the full article, please register now for access

It's completely free